Innate Pharma S.A.

IPHANASDAQHealthcare● Active

$1.76

+$0.05(+2.92%)

Market Cap$165269787

P/E Ratio—

52W High$2.63

52W Low$1.17

Avg Volume68K

Open$1.73

Beta0.89

Free Cash Flow Financials Revenue

Innate Pharma S.A. (IPHA) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

IPHA · free cash flow · updated Jun 8, 2026

Core FCF metrics

IPHA · FCF · TTM · margin & CAGR

Free cash flow was −$50.8M for FY2025 (fiscal year ending 2025-12-31), down 597.2% year-over-year

FY2025 Free Cash Flow−$50.8M▼ -597.2% YoY

Trailing 12M (TTM)−$64.9Mtrailing 4 quarters sum

FCF Margin< −999%−$50.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

IPHA · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$50.7M(0M)−$50.8M▼ 597.2%—

FY2024−$6.9M(0M)−$7.3M▲ +79.1%-57.7%

FY2023−$32.6M(2M)−$34.9M▼ 72.2%-67.3%

FY2022−$19.2M(1M)−$20.3M▲ +66.1%-35.2%

FY2021−$58.5M(1M)−$59.8M▲ +5.2%-493.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

IPHA · P/FCF · FCF yield · FCF per share

Innate Pharma S.A. (IPHA) reported negative free cash flow of −$0.05B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

IPHA · cash flow statement · operating / investing / financing

For FY2025, Innate Pharma S.A. generated −$50.7M in operating cash flow and spent 0M in capital expenditures, yielding −$50.8M in free cash flow.

Operating Activities

−$50.7M

Cash from core business operations

2025-12-31

Investing Activities

+$7.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$5.8M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$50.7M) − |CapEx| (0M) = FCF (−$50.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

IPHA vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Innate Pharma S.A.YOU

IPHA

−$50.8M-597.2%-1823.0%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Innate Pharma S.A. (IPHA) reported free cash flow of −$50.8M for FY2025 (fiscal year ending 2025-12-31), down 597.2% year-over-year.

Based on available data, Innate Pharma S.A. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $200.5M in FY2015.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

IPHA free cash flow · 8 questions

Innate Pharma S.A. free cash flow was −$50.8M for FY2025, down 597.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$64.9M.

IPHA free cash flowIPHA FCFIPHA FCF 2025IPHA free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Innate Pharma S.A. · Innate Pharma S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026